A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency
Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
About this trial
This is an interventional treatment trial for Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of homocystinuria due to CBS deficiency
- Capable of providing signed informed consent/assent and to comply with all study related procedures
- Is ≥12 years of age (≥18 in the US) at the time of signing the informed consent/assent
- Plasma tHcy >80 µM
- Female subjects of child-bearing potential must have a negative serum pregnancy test during the screening period and a negative urine pregnancy test prior to dosing on the first day of treatment
- If the subject (male or female) is engaging in sexual activity, he/she must be unable to become pregnant/cause pregnancy or must agree to use highly effective contraception
- Willing to maintain a stable diet with no significant modifications while on study
Exclusion Criteria:
- Other medical conditions or co-morbidity(ies) that, in the opinion of the investigator, would interfere with study compliance or data interpretation (eg, severe intellectual disability that precludes completion of the required study assessments)
- Currently participating in another therapeutic clinical study or has received any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug in this study
- Surgery requiring general anesthesia within 8 weeks prior to the first dose of study drug
- Active infection requiring anti-infective therapy <2 weeks prior to the first dose of study drug in this study; anti-infective therapy that completes ≥2 weeks prior to first dose of study drug is acceptable
- Pregnant or nursing
- Females of child-bearing potential who are using or plan to use estrogen-containing contraception during the study
- History of hypersensitivity to polyethylene glycol (PEG) that, in the judgment of the investigator, puts the subject at unacceptable risk for adverse events (AEs)
- Serum creatinine level >1.5× the upper limit of normal (ULN)
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin level > 2× the ULN
Sites / Locations
- UT Southwestern Medical Center
- Westmead Hospital
- Royal Children's Hospital
- Royal Melbourne Hospital
- University Hospitals Birmingham NHS
- Great Ormond Street Hospital
- Guy's and St Thomas' Hospital NHS Foundation Trust
- University College London
- Salford Royal NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Pegtarviliase Cohort 1
Pegtarviliase Cohort 2
Pegtarviliase Cohort 3
Pegtarviliase Cohort 4
Pegtarviliase Cohort 5
Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose C weekly for a total of 4 doses
Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose D weekly for a total of 4 doses
Optional cohort for up to 12 subjects ≥12 years of age (≥18 in the US) dosing at Dose E weekly for a total of 13 doses